Pill approved specifically for African Americans

Discussion in 'Race Relations' started by kazenatsu, Jun 29, 2018.

  1. kazenatsu

    kazenatsu Well-Known Member Past Donor

    Joined:
    May 15, 2017
    Messages:
    34,608
    Likes Received:
    11,192
    Trophy Points:
    113
    In June 2005 the FDA approved BiDil, a pharmaceutical drug specifically approved for African Americans. An antihypertensive for patients with congestive heart failue, it was the first race-based prescription drug in American history. BiDil’s release generated controversy. Some, including the NAACP and the Congressional Black Caucus, praised it as a step towards better addressing the often under-served and overlooked healthcare needs of Black patients. Others called it pseudoscientific medical racism.

    BiDil was not originally intended to be race-specific. It’s development began in the early 1980s when the University of Minnesota collaborated with the Veterans Administration to develop a new treatment for heart failure. They found promising early results with a combination of hydralazine and isosorbide dinitrate and received a patent in 1989. A company called Medco licensed the patent and spent several years preparing an application to seek FDA approval. But the FDA rejected the application, saying that clinical trial data did not sufficiently prove the treatment was actually effective.

    Dr. Jay Cohn, the cardiologist who organized the trials, reanalyzed the data and found that the drug seemed to work better in patients who had self-identified themselves as African Americans. He saw this as spectacular news, because it was widely known that the conventional drugs for treating hypertension in patients with Congestive Heart Failure were substantially less effective for Black patients.

    With this new hypothesis, the parent was licensed to a different company, NitroMed, who then ran the African-American Heart Failure Trial. The new drug seemed like a miracle! In Black Congestive Heart Failure patients, it reduced hospitalizations by 39 percent, and mortality by 43 percent. The drug was so successful that the trial was ended early to avoid additional deaths among the patients in the study who were receiving a placebo. The FDA approved the drug, and BiDil was quickly added to the standard treatment guidelines for treating Congestive Heart Failure.

    Anita Patel, M.D., transplant nephrologist at Henry Ford Hospital, found that kidney transplants between individuals of the same race had statistically better outcomes than transplants across different races:
    http://www.time.com/time/health/article/0,8599,1993074,00.html
     
    Last edited: Jun 29, 2018
  2. DarkSkies

    DarkSkies Well-Known Member

    Joined:
    Dec 15, 2014
    Messages:
    4,522
    Likes Received:
    583
    Trophy Points:
    113
    Folks, Bidil is actually a failed drug. Also, the 2005 article is more than a decade old and more recent studies on this drug (2017) renders the OP obsolete.
     
    Bowerbird likes this.
  3. kazenatsu

    kazenatsu Well-Known Member Past Donor

    Joined:
    May 15, 2017
    Messages:
    34,608
    Likes Received:
    11,192
    Trophy Points:
    113
    The actual truth is much more mixed.
    https://www.medpagetoday.com/cardiology/cardiobrief/62687
    The fact that it ultimately failed commercially does not mean that it was completely ineffective for specifically treating Black patients.

    Two of the reasons why it failed to gain commercial traction were higher costs of a brand name drug, and the fact that several new more effective classes of drugs were later developed for heart failure.
     
    Last edited: Jun 30, 2018
  4. DarkSkies

    DarkSkies Well-Known Member

    Joined:
    Dec 15, 2014
    Messages:
    4,522
    Likes Received:
    583
    Trophy Points:
    113
    The problem with the drug was that not enough doctors trusted it and they didn't for good reasons. The trial with just the African Americans was done in conjunction with medications that are known to work on heart failure anyway. There were other research methodology flaws that contributed to its distrust and ultimately why it failed.
     

Share This Page